Total Funding
57
55
Total FundingPost-IPO Debt raised
Growth Score 57 in past quarter
-23 pts
Heat Score 55 in past quarter
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
97197
Awakn Life Sciences is an ecosystem for psychedelic-based treatments.
- Shaun McNulty: Chief Scientific OfficerPast Role: Biosceptre, Chief Scientific Officer
Dennis Purcell: CEOPast Role: Paratek Pharmaceuticals, Director
About the Company
Awakn Life Sciences is a biotechnology company with clinical operations that develops and delivers psychedelic medicine to better treat addiction. Awakn's team consists of chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to
treat addiction.